MX2021006342A - Mutantes de virus de influenza y usos para los mismos. - Google Patents

Mutantes de virus de influenza y usos para los mismos.

Info

Publication number
MX2021006342A
MX2021006342A MX2021006342A MX2021006342A MX2021006342A MX 2021006342 A MX2021006342 A MX 2021006342A MX 2021006342 A MX2021006342 A MX 2021006342A MX 2021006342 A MX2021006342 A MX 2021006342A MX 2021006342 A MX2021006342 A MX 2021006342A
Authority
MX
Mexico
Prior art keywords
influenza virus
compositions
uses therefor
mutant
virus mutants
Prior art date
Application number
MX2021006342A
Other languages
English (en)
Inventor
Pamuk Bilsel
Yasuko Hatta
Original Assignee
Flugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flugen Inc filed Critical Flugen Inc
Publication of MX2021006342A publication Critical patent/MX2021006342A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation
    • C12N2760/16262—Methods of inactivation or attenuation by genetic engineering

Abstract

Se describen composiciones y métodos relacionados con virus mutantes, y en particular, virus de influenza mutantes. Los virus mutantes aquí descritos incluyen una secuencia M2 mutante; y son útiles en composiciones inmunogénicas, por ejemplo, como vacunas. También aquí se describen métodos, composiciones y células para propagar los mutantes virales, y métodos, dispositivos y composiciones relacionadas con la vacunación.
MX2021006342A 2011-06-24 2014-01-07 Mutantes de virus de influenza y usos para los mismos. MX2021006342A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161501034P 2011-06-24 2011-06-24

Publications (1)

Publication Number Publication Date
MX2021006342A true MX2021006342A (es) 2022-05-26

Family

ID=47423213

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014000254A MX346625B (es) 2011-06-24 2012-06-21 Mutantes de virus de influenza y usos para los mismos.
MX2017003936A MX361139B (es) 2011-06-24 2012-06-21 Mutantes de virus de influenza y usos para los mismos.
MX2021006342A MX2021006342A (es) 2011-06-24 2014-01-07 Mutantes de virus de influenza y usos para los mismos.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2014000254A MX346625B (es) 2011-06-24 2012-06-21 Mutantes de virus de influenza y usos para los mismos.
MX2017003936A MX361139B (es) 2011-06-24 2012-06-21 Mutantes de virus de influenza y usos para los mismos.

Country Status (11)

Country Link
US (6) US9284533B2 (es)
EP (3) EP2723855B1 (es)
JP (6) JP6253576B2 (es)
KR (7) KR102628482B1 (es)
CN (3) CN109652430B (es)
AU (5) AU2012272837B2 (es)
CA (4) CA3055006C (es)
DK (2) DK2723855T3 (es)
ES (1) ES2890427T3 (es)
MX (3) MX346625B (es)
WO (1) WO2012177924A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
US9109013B2 (en) 2009-10-26 2015-08-18 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
EP2590971A4 (en) 2010-06-17 2014-12-10 Fuzians Biomedicals Inc COMPOUNDS USEFUL AS ANTIVIRAL AGENTS, COMPOSITIONS, AND METHODS OF USE
KR102628482B1 (ko) * 2011-06-24 2024-01-23 플루젠, 인코퍼레이티드 인플루엔자 바이러스 돌연변이체들 및 그들의 용도들
CN104056276B (zh) * 2013-03-20 2017-05-10 上海生物制品研究所有限责任公司 一种流感病毒减毒活疫苗及其制备方法
WO2015009743A1 (en) 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
WO2015142671A2 (en) * 2014-03-17 2015-09-24 Flugen, Inc. Influenza virus vectors and uses therefor
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
US11197925B2 (en) 2016-02-19 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
CA3054578A1 (en) * 2017-02-27 2018-08-30 Flugen, Inc. Immunogenic compositions against influenza
US11529409B2 (en) * 2017-02-27 2022-12-20 Flugen, Inc. Influenza B virus mutants and uses therefor
CN107151659B (zh) * 2017-03-01 2021-04-02 苏州系统医学研究所 一种流感病毒株及其应用
WO2020167432A2 (en) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
KR102370100B1 (ko) * 2019-02-15 2022-03-07 아이디바이오 주식회사 이종 인플루엔자 a 바이러스에 대한 면역/치료반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 유전자 전달체 및 치료백신
US11214799B2 (en) * 2019-03-12 2022-01-04 The University Court Of The University Of Edinburg Old College HA-specific influenza virus attenuated vaccine comprising mutations in segment 7, and uses therefor
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
CN110468130B (zh) * 2019-08-09 2021-08-06 中国人民解放军军事科学院军事医学研究院 流感长链非编码RNA-lnc330及其应用
EP4022046A2 (en) 2019-08-27 2022-07-06 Wisconsin Alumni Research Foundation (WARF) Recombinant influenza viruses with stabilized ha for replication in eggs
MX2023000881A (es) 2020-07-21 2023-02-22 Flugen Inc Estructura genomica del virus de la influenza.
CN114381439B (zh) * 2022-01-27 2023-12-15 浙江迪福润丝生物科技有限公司 一种同义突变结合删除突变的流感病毒的致弱方法及致弱流感病毒株和应用
CN114410681B (zh) * 2022-01-27 2024-02-13 浙江迪福润丝生物科技有限公司 一种基于m基因核苷酸片段删除的流感病毒的致弱方法以及致弱流感病毒株和应用
CN114438043B (zh) * 2022-01-27 2023-12-15 浙江迪福润丝生物科技有限公司 一种区分感染和免疫的致弱流感病毒疫苗株及疫苗
CN114381440B (zh) * 2022-01-27 2023-12-15 浙江迪福润丝生物科技有限公司 一组基于同义突变和/或缺失突变的a型流感病毒致弱毒株及其制备方法和应用
CN114381438B (zh) * 2022-01-27 2024-02-02 浙江迪福润丝生物科技有限公司 一种流感病毒的致弱方法及流感致弱病毒株和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0948676A4 (en) 1996-12-20 2002-05-08 Procter & Gamble DRY-PRODUCED STRUCTURE CONTAINING PARTICULATE MATERIAL
GB9815040D0 (en) * 1998-07-10 1998-09-09 Medical Res Council Conditional mutant
US6872395B2 (en) 2000-04-14 2005-03-29 Wisconsin Alumni Research Foundation Viruses comprising mutant ion channel protein
EP1364006A2 (en) 2001-02-23 2003-11-26 Wisconsin Alumni Research Foundation Methods to identify mutant cells with altered sialic acid
NZ542935A (en) 2003-04-23 2008-08-29 Wisconsin Alumni Res Found Recombinant influenza viruses holding a mutation in a transmembrane protein gene
US8475806B2 (en) * 2003-05-28 2013-07-02 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines and gene therapy
WO2005020912A2 (en) * 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
CN1810961B (zh) * 2006-02-22 2010-05-12 中国人民解放军军事医学科学院微生物流行病研究所 一种重组流感病毒及其制备方法与应用
US9474798B2 (en) * 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
MX2010005244A (es) * 2007-11-12 2010-10-25 Theraclone Sciences Inc Composiciones y métodos para la terapia y el diagnóstico de influenza.
EP2296701A1 (en) 2008-06-11 2011-03-23 Flugen, Inc. Cell-based systems for producing influenza vaccines
US20100061995A1 (en) * 2008-09-08 2010-03-11 Damian Michael Carragher Immunotherapy To Treat Or Prevent Viral Infection
JP2012525133A (ja) * 2009-05-01 2012-10-22 レッドバイオテック・アーゲー 多重遺伝子ベクターによってコードされる組換えウイルス様粒子
US20110172609A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
US20110172639A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Device and method for delivery of microneedle to desired depth within the skin
US20110172638A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Drug delivery device including multi-functional cover
US20110172637A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Drug delivery device including tissue support structure
US20110172645A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Wearable drug delivery device including integrated pumping and activation elements
WO2012061556A1 (en) 2010-11-03 2012-05-10 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
TW201303143A (zh) 2011-03-22 2013-01-16 Exxonmobil Upstream Res Co 低排放渦輪機系統中用於攫取二氧化碳及產生動力的系統與方法
KR102628482B1 (ko) * 2011-06-24 2024-01-23 플루젠, 인코퍼레이티드 인플루엔자 바이러스 돌연변이체들 및 그들의 용도들
JP6120237B1 (ja) 2016-06-20 2017-04-26 仁博 平嶋 サービスシステム、アプリケーションプログラム及び決済方法
JP6639334B2 (ja) 2016-06-20 2020-02-05 株式会社日立製作所 業務処理フロー生成システム、生成方法および装置

Also Published As

Publication number Publication date
JP2018046851A (ja) 2018-03-29
JP6496000B2 (ja) 2019-04-03
US9919042B2 (en) 2018-03-20
CN103781901B (zh) 2019-04-12
JP7231666B2 (ja) 2023-03-01
MX361139B (es) 2018-11-28
CN109652430A (zh) 2019-04-19
EP3447131B1 (en) 2021-08-18
JP2023071764A (ja) 2023-05-23
KR20180094145A (ko) 2018-08-22
AU2012272837A2 (en) 2014-01-30
AU2023204165A1 (en) 2023-08-03
JP6445662B2 (ja) 2018-12-26
MX2014000254A (es) 2014-10-14
KR102080061B1 (ko) 2020-02-21
AU2020201760B2 (en) 2023-04-20
US20200061182A1 (en) 2020-02-27
JP6870017B2 (ja) 2021-05-12
KR102080062B1 (ko) 2020-02-21
AU2018200490A1 (en) 2018-02-15
KR20210084710A (ko) 2021-07-07
KR20220133316A (ko) 2022-10-04
AU2018200488A1 (en) 2018-02-08
KR20140037235A (ko) 2014-03-26
KR20180094147A (ko) 2018-08-22
AU2018200490B2 (en) 2020-03-19
AU2012272837B2 (en) 2017-11-02
AU2018200488B2 (en) 2020-03-19
CN103781901A (zh) 2014-05-07
KR20200021100A (ko) 2020-02-27
KR102080914B1 (ko) 2020-02-26
CN109652430B (zh) 2023-05-16
CN106995802A (zh) 2017-08-01
KR102275459B1 (ko) 2021-07-09
CA3055002C (en) 2021-02-09
EP2723855A2 (en) 2014-04-30
US20190060441A1 (en) 2019-02-28
CA3055006C (en) 2021-02-09
CA2875484A1 (en) 2012-12-27
KR102446975B1 (ko) 2022-09-22
US9284533B2 (en) 2016-03-15
JP2014526883A (ja) 2014-10-09
US20140127249A1 (en) 2014-05-08
US9919043B2 (en) 2018-03-20
WO2012177924A3 (en) 2013-09-06
KR102628482B1 (ko) 2024-01-23
KR20240013286A (ko) 2024-01-30
CN106995802B (zh) 2021-04-09
MX346625B (es) 2017-03-27
EP2723855B1 (en) 2018-08-08
JP2018046850A (ja) 2018-03-29
JP2021112196A (ja) 2021-08-05
US11207399B2 (en) 2021-12-28
NZ620242A (en) 2016-02-26
EP4023749A1 (en) 2022-07-06
EP2723855A4 (en) 2015-01-07
EP3447131A1 (en) 2019-02-27
JP2019103516A (ja) 2019-06-27
US20220409719A1 (en) 2022-12-29
JP6253576B2 (ja) 2017-12-27
US20160228535A1 (en) 2016-08-11
WO2012177924A2 (en) 2012-12-27
DK3447131T3 (da) 2021-09-13
DK2723855T3 (en) 2018-10-01
CA3055002A1 (en) 2012-12-27
AU2012272837A1 (en) 2014-01-16
CA3103774A1 (en) 2012-12-27
ES2890427T3 (es) 2022-01-19
US20160228534A1 (en) 2016-08-11
CA2875484C (en) 2019-11-05
CA3055006A1 (en) 2012-12-27
AU2020201760A1 (en) 2020-03-26
US11040098B2 (en) 2021-06-22

Similar Documents

Publication Publication Date Title
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
WO2015142671A3 (en) Influenza virus vectors and uses therefor
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
MX2023000211A (es) Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
PH12017500727A1 (en) Modified virus-like particles of cmv
WO2010019262A3 (en) Polyvalent vaccine
MX2013014109A (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
UA112768C2 (uk) Європейський штам prrsv
WO2013054199A3 (en) Cmv antigens and uses thereof
WO2006063053A3 (en) Methods of producing influenza vaccine compositions
MX2010003713A (es) Vacunas de citomegalovirus y metodos de produccion.
MX2013013800A (es) Oligodesoxinucleotidos inmunoestimuladores.
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
NZ603863A (en) Concentration and lyophilization of influenza vaccine antigens
WO2011106607A3 (en) Subunit vaccines for herpes viruses and methods of use
WO2009115917A3 (en) Improvements in preparation of influenza virus vaccine antigens
PL2658570T3 (pl) Sposoby i kompozycje szczepionki przeciwko wirusowi wirusowej biegunki bydła typu 1b
MX349294B (es) Formulaciones virales liofilizadas.
EP2643014A4 (en) HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
WO2013052095A3 (en) Vaccine
WO2013026452A9 (en) Method for removing immunosuppresive properties of hiv envelope glycoproteins
MX350718B (es) Vacuna de rinitis equina.
NZ756582A (en) Immunogenic compositions against influenza
MX2012002702A (es) Vacuna de herpesvirus bovino.